PDF(Sci-hub)
Abstract：
BACKGROUND: We aimed to examine the contribution of subjective cognitive decline (SCD) to reduce the number of β-amyloid (Aβ) positron emission tomography scans required for recruiting Aβ+ clinically normal individuals in clinical trials.
METHODS: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age.
RESULTS: SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known.
CONCLUSIONS: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.
METHODS: Three independent cohorts (890 clinically normal: 72 yrs ± 6.7; Female: 43.4%; SCD+: 24%; apolipoprotein E [APOE] ε4+: 28.5%; Aβ+: 32%) were used. SCD was dichotomized from one question. Using logistic regression, we classified Aβ+ using the SCD dichotomy, APOEε4, sex, and age.
RESULTS: SCD increased odds of Aβ+ by 1.58 relative to non-SCD. Female APOEε4 carriers with SCD exhibited higher odds of Aβ+ (OR = 3.34), whereas male carriers with SCD showed a weaker, opposing effect (OR = 0.37). SCD endorsement reduces the number of Aβ positron emission tomography scans to recruit Aβ+ individuals by 13% and by 9% if APOEε4 status is known.
CONCLUSIONS: SCD helps to classify those with high Aβ, even beyond the substantial effect of APOE genotype. Collecting SCD is a feasible method for targeting recruitment for those likely on the AD trajectory.
摘要：
背景：我们旨在研究主观认知功能下降（SCD）对减少临床试验中招募Aβ+临床正常个体所需的β-淀粉样蛋白（Aβ）正电子发射断层扫描数量的贡献。
方法：使用三个独立的队列（890例临床正常：72岁±6.7；女性：43.4％；SCD：24％；载脂蛋白E[APOE]ε4：28.5％；Aβ：32％）。SCD是从一个问题中区分出来的。使用逻辑回归，我们使用SCD二分法对Aβ+进行分类，APOEε4，性，和年龄。
结果：SCD与非SCD相比，Aβ+的几率增加了1.58。患有SCD的女性APOEε4携带者表现出更高的Aβ+几率（OR=3.34），而患有SCD的男性携带者表现较弱，相反效应(OR=0.37)。SCD认可将招募Aβ+个体的Aβ正电子发射断层扫描的数量减少了13%，如果APOEε4状态已知，则减少了9%。
结论：SCD有助于对高Aβ的患者进行分类，甚至超出了APOE基因型的实质性影响。收集SCD是针对那些可能在AD轨迹上的招募的可行方法。
方法：使用三个独立的队列（890例临床正常：72岁±6.7；女性：43.4％；SCD：24％；载脂蛋白E[APOE]ε4：28.5％；Aβ：32％）。SCD是从一个问题中区分出来的。使用逻辑回归，我们使用SCD二分法对Aβ+进行分类，APOEε4，性，和年龄。
结果：SCD与非SCD相比，Aβ+的几率增加了1.58。患有SCD的女性APOEε4携带者表现出更高的Aβ+几率（OR=3.34），而患有SCD的男性携带者表现较弱，相反效应(OR=0.37)。SCD认可将招募Aβ+个体的Aβ正电子发射断层扫描的数量减少了13%，如果APOEε4状态已知，则减少了9%。
结论：SCD有助于对高Aβ的患者进行分类，甚至超出了APOE基因型的实质性影响。收集SCD是针对那些可能在AD轨迹上的招募的可行方法。
